Literature DB >> 1680552

17p allelic deletions and p53 protein overexpression in Barrett's adenocarcinoma.

P L Blount1, S Ramel, W H Raskind, R C Haggitt, C A Sanchez, P J Dean, P S Rabinovitch, B J Reid.   

Abstract

Barrett's esophagus is a condition in which the stratified squamous epithelium of the esophagus is replaced by metaplastic columnar epithelium that predisposes to the development of esophageal adenocarcinoma. Allelic deletions of 17p and alterations of p53 including elevated p53 protein levels have been observed in many different tumors. To investigate the presence of 17p allelic deletions and p53 protein overexpression in Barrett's adenocarcinomas, we have combined the use of restriction fragment length polymorphism analysis, multiparameter flow cytometry, and DNA content cell sorting. The combined use of these methodologies permits the purification of aneuploid tumor cells for restriction fragment length polymorphism analysis of 17p allelic deletions and the evaluation of p53 protein expression by multiparameter flow cytometry in the same aneuploid tumor cell populations. We analyzed 15 aneuploid populations and one tetraploid populations from 13 Barrett's adenocarcinomas for 17p allelic deletions and p53 protein overexpression to determine whether both of these alterations are involved in carcinogenesis in Barrett's esophagus. Twelve of 13 tumors (92%) had 17p allelic deletions, and 8 of 13 tumors (62%) had p53 protein overexpression. Eight of the 12 tumors (67%) with 17p allelic deletions also had p53 protein overexpression. These data indicate that both 17p allelic deletions and p53 protein overexpression are frequently involved in carcinogenesis in Barrett's esophagus.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1680552

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  29 in total

Review 1.  Molecular biology of Barrett's adenocarcinoma.

Authors:  B P Wijnhoven; H W Tilanus; W N Dinjens
Journal:  Ann Surg       Date:  2001-03       Impact factor: 12.969

Review 2.  Screening and surveillance for Barrett's esophagus: current issues and future directions.

Authors:  Sung E Choi; Chin Hur
Journal:  Curr Opin Gastroenterol       Date:  2012-07       Impact factor: 3.287

3.  A new approach for the surgical treatment of Barrett's esophagus.

Authors:  K D Lillemoe
Journal:  Ann Surg       Date:  1997-08       Impact factor: 12.969

4.  The development of a fluorescence in situ hybridization assay for the detection of dysplasia and adenocarcinoma in Barrett's esophagus.

Authors:  Shannon M Brankley; Kenneth K Wang; Aaron R Harwood; Dylan V Miller; Mona S Legator; Lori S Lutzke; Benjamin R Kipp; Larry E Morrison; Kevin C Halling
Journal:  J Mol Diagn       Date:  2006-05       Impact factor: 5.568

Review 5.  Role of p53 assessment in management of Barrett's esophagus.

Authors:  A K Kubba; N A Poole; A Watson
Journal:  Dig Dis Sci       Date:  1999-04       Impact factor: 3.199

6.  Genotypic analysis of multiple loci in somatic cells by whole genome amplification.

Authors:  M T Barrett; B J Reid; G Joslyn
Journal:  Nucleic Acids Res       Date:  1995-09-11       Impact factor: 16.971

7.  Adenocarcinoma arising in Barrett's oesophagus: evidence for the participation of p53 dysfunction in the dysplasia/carcinoma sequence.

Authors:  R H Hardwick; N A Shepherd; M Moorghen; P V Newcomb; D Alderson
Journal:  Gut       Date:  1994-06       Impact factor: 23.059

Review 8.  Multimodality treatment of cancer arising from Barrett's epithelium.

Authors:  J A Roth
Journal:  World J Surg       Date:  1995 Mar-Apr       Impact factor: 3.352

Review 9.  Barrett's esophagus: model of neoplastic progression.

Authors:  Stig Ramel
Journal:  World J Surg       Date:  2003-08-18       Impact factor: 3.352

Review 10.  Barrett's esophagus: pathogenesis, epidemiology, functional abnormalities, malignant degeneration, and surgical management.

Authors:  H J Stein; J R Siewert
Journal:  Dysphagia       Date:  1993       Impact factor: 3.438

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.